Monthly tracking report: genetic testing, precision medical planning to promote industry development and application
In June, the pharmaceutical and biological industry rose by 4.13%, an increase of 4.58 percentage points from the month of May, and it beat the Shanghai and Shenzhen 3004.62 percentage points, ranking 13th among the 28 Shenwan sub-sectors. In terms of sub-sectors, all sectors rose. The best performer was the Chinese medicine sector, which rose 5.00%.
In June, the pharmaceutical bio-industry PE (TTM) valuation was 39.97 times, compared with the Shanghai and Shenzhen 300 valuation premium rate of 233.64%, which is about the median level in the Shenwan industry. Compared with last year, the valuation level is low, and the valuation level has increased compared with May.
In terms of sub-sectors, the medical device segment PE(TTM) has the highest valuation, and the premium rate relative to the CSI 300 is 502.42%.
Industry operation data
In May 2016, the main business income of the pharmaceutical manufacturing industry totaled 1.04 trillion yuan, a cumulative increase of 10.3% year-on-year, and maintained steady growth. The monthly main business income was 217.20 billion yuan, up 8.5% year-on-year and 2.08% quarter-on-quarter; the total profit was 107.97 billion yuan, a cumulative year-on-year increase of 15.20%, and the monthly profit was 21.75 billion yuan, up 13.5% year-on-year and 5.56% quarter-on-quarter. .
Investment Advice
Since the United States and China have successively proposed accurate medical plans, genetic testing technology has become more and more interesting. Under this craze, many domestic genetic testing projects started to operate, and many companies actively deployed precision medical treatment, and the industry has developed rapidly and applied. It is recommended to pay attention to the Da'an Gene and Dean Diagnostics, which have entered the industry earlier, are larger in scale, superior in technology, and strong in research and development. Through investment subsidiary layout, they have entered the industry with potential for development, such as Lepu Medical and Kehua Biological.
risk warning
Volatility risk with the broader market trend;
Risk of industry pressure caused by the introduction of policies;
Possible drug safety, medical event related risks
The risk of the investment not meeting the expected return
Feline Infectious Peritonitis (FIP), referred to as Feline Infectious Peritonitis (FIP), is a fatal abnormal immune response that occurs in cats. It is caused by the mutation of the feline coronavirus carried by cats. As a high-incidence and fatal disease of pet cats, the current incidence of feline abdominal transmission is about 10%.
The symptoms of cats are usually divided into two categories, namely wet FIP and dry FIP, of which wet FIP accounts for the majority of all cases. About 70%, manifested as abdominal pleural effusion, abnormal bulging; dry FIP cats have different symptoms, depending on the type of organ affected by the virus.
So far, all feline feline feline treatments are based on the characteristics of the disease, and GS-441524 can play a role in the treatment of feline feline disease. Therefore, the therapeutic effect of GS-441524 is obviously more ideal, the dose used is less, the treatment cycle is shorter, and the efficacy, safety and convenience of operation are all good. Because of this, GS-441524 is considered by many pet owners and veterinarians to be a magic medicine that can effectively treat feline abdominal infection.
Gs 441524 Fip,Fip Treatment Gs441,Gs 441524 Fipv Cats,Gs 441524 For Fip
XI AN RHINE BIOLOGICAL TECHNOLOGY CO.,LTD , https://www.rhinebiotech.com